A follow-up study on features of sensory gating P50 in treatment-resistant depression patients

Chinese Medical Journal

Volumn 122, Issue 24, 2009, Pages 2956-2960

  Wang, Yong ^a   Fang, Yi Ru ^a   Chen, Xing Shi ^a   Chen, Jun ^a   Wu, Zhi Guo ^a   Yuan, Cheng Mei ^a   Yi, Zheng Hui ^a   Hong, Wu ^a   Zhang, Chen ^a   Cao, Lan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biological markers; Evoked potentials, auditory; Sensory gating; Treatment resistant depression

Indexed keywords

PROTEIN P50; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; AMPLITUDE MODULATION; ARTICLE; AUDITORY STIMULATION; CHANNEL GATING; CLINICAL FEATURE; COMPARATIVE STUDY; CONDITIONING; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE COURSE; ELECTROPHYSIOLOGY; EVOKED AUDITORY RESPONSE; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PROTEIN EXPRESSION; TREATMENT DURATION;

ACOUSTIC STIMULATION; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REACTION TIME; SENSORY GATING; YOUNG ADULT;

EID: 74549148317     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.24.007     Document Type: Article

References (21)

1. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res 2002; 53: 849-857.
2. Lu J, Ruan Y, Huang Y, Yao J, Dang W, Gao C. Major depression in Kunming: prevalence, correlates and co-morbidity in a south-western city of China. J Affect Disord 2008; 111: 221-226.
3. Hwu HG, Chang IH, Yeh EK, Chang CJ, Yeh LL. Major depressive disorder in Taiwan defined by the Chinese diagnostic Interview Schedule. J Nerv Ment Dis 1996; 184: 497-502.
4. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 179-200.
5. Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dubé EM. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002; 63: 577-584.
6. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58: 23-29.
7. Light GA, Braff DL. Do self-reports of perceptual anomalies reflect gating deficits in schizophrenia patients. Biol Psychiatry 2000; 47: 463-467.
8. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 2000; 157: 767-771.
9. Olincy A, Ross RG, Harris JG, Young DA, McAndrews MA, Cawthra E, et al. The P50 auditory event-evoked potential in adult attention-deficit disorder: comparison with schizophrenia. Biol Psychiatry 2000; 47: 969-977.
10. Olincy A, Martin L. Diminished suppression of the P50 auditory evoked potential in bipolar disorder subjects with a history of psychosis. Am J Psychiatry 2005; 162: 43-49.
11. Jiang KD, Su H, Chen XS, Lou FY, Liang JH, Chen XW. Sensory gating deficits assessed by the P50 event-related potential in subjects with first-episode depression. Chin J Psychiatry (Chin) 2006; 39: 197-200.
12. Chen XS, Wang HX, Zhang MD. Study advancements on sensory gating theory and animal model of schizophrenia. Chin J Psychiatry (Chin) 2006; 39: 247-249.
13. Liu QR, Huang BC, Sun JL. Practical clinical electrophysiology. Beijing: Chinese Scientific & Technology Publishing; 2006: 95-108.
14. Smith DA, Boutros NN, Schwarzkopf SB. Reliability of P50 auditory event-related potential indices of sensory gating. Psychophysiology 1994; 31: 495-502.
15. Chen XS, Zhang MD, Lou FY, Wang HX, Wang JJ, Guo Q, et al. Follow-up study on sensory gating in first-episode schizophrenia. Chin J Psychiatry (Chin) 2006; 39: 193-196.
16. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 1997; 94: 587-592.
17. Schulze KK, Hall MH, McDonald C, Marshall N, Walshe M, Murray RM, et al. P50 auditory evoked potential suppression in bipolar disorder patients with psychotic features and their unaffected relatives. Biol Psychiatry 2007; 62: 121-128.
18. Light GA, Malaspina D, Geyer MA, Luber BM, Coleman EA, Sackeim HA, et al. Amphetamine disrupts P50 suppression in normal subjects. Biol Psychiatry 1999; 46: 990-996.
19. Chen XS, Lu YZ, Wang JJ, Wang HX, Zhang MD, Lou FY, et al. Relationship between event-related potential P300 and first episode schizophrenia. Chin Med J 2007; 120: 339-341.
20. Jain R. Single-action versus dual-action antidepressants. Prim Care Companion J Clin Psychiatry 2004; 6: 7-11.
21. Wang Y, Fang YR, Chen XS. Study advancements on sensory gating P50 of mental disorders. J Neurol Neurorehabilitation 2007; 4: 199-200.